file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 17722, GCS 106366, CR 136943 Collection span: 1963 - 2012 | |
Word(i) List (4568) Word count: 24159, All words count: 34321 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
801 | CONTINUOUS | 2 | 19 | 87 |
802 | CYCLOSPORINE-INDUCED | 6 | 19 | 239 |
803 | DISTRIBUTION | 5 | 19 | 199 |
804 | DOSE-DEPENDENCE | 1 | 19 | 117 |
805 | FLEXIBLE | 1 | 19 | 316 |
806 | FLT-3 | 3 | 19 | 49 |
807 | FORBIDDEN | 1 | 19 | 60 |
808 | GLUCOSE-TOLERANCE | 1 | 19 | 29 |
809 | H-Y | 4 | 19 | 31 |
810 | HIGH-RISK | 5 | 19 | 132 |
811 | HOMOTRANSPLANT | 2 | 19 | 152 |
812 | HYPERSENSITIVITY | 5 | 19 | 236 |
813 | HYPERTENSION | 14 | 19 | 553 |
814 | IMMUNOMODULATION | 5 | 19 | 46 |
815 | ISOLATED | 6 | 19 | 254 |
816 | LARGE | 9 | 19 | 157 |
817 | MAB | 2 | 19 | 86 |
818 | MULTIVISCERAL | 11 | 19 | 133 |
819 | P450-3A | 1 | 19 | 102 |
820 | PROCUREMENT | 4 | 19 | 325 |
821 | REFERENCES | 1 | 19 | 60 |
822 | SODIUM | 5 | 19 | 138 |
823 | SPITE | 2 | 19 | 32 |
824 | SUPERIORITY | 2 | 19 | 31 |
825 | TYPES | 2 | 19 | 164 |
826 | UNDERGO | 1 | 19 | 20 |
827 | UNFINISHED | 2 | 19 | 66 |
828 | ADJUVANT | 7 | 18 | 199 |
829 | ALLOREACTIVE | 5 | 18 | 65 |
830 | ANTIPROLIFERATIVE | 2 | 18 | 137 |
# | Word | Recs | TLCS | TGCS |
831 | ANTISERA | 5 | 18 | 95 |
832 | BRIEF | 3 | 18 | 77 |
833 | CELL-SPECIFIC | 1 | 18 | 33 |
834 | CHALLENGES | 8 | 18 | 151 |
835 | CYCLOSPORINE-BASED | 3 | 18 | 121 |
836 | DONOR-TYPE | 8 | 18 | 55 |
837 | DYSFUNCTION | 6 | 18 | 134 |
838 | EMPHASIS | 4 | 18 | 80 |
839 | ENTERS | 1 | 18 | 57 |
840 | IDENTICAL | 4 | 18 | 95 |
841 | IMMATURE | 3 | 18 | 82 |
842 | IMPROVEMENT | 1 | 18 | 68 |
843 | INDUCES | 6 | 18 | 544 |
844 | INFECTIONS | 8 | 18 | 317 |
845 | KIDNEY-FUNCTION | 1 | 18 | 68 |
846 | LOSS | 6 | 18 | 226 |
847 | LYMPHOLD | 1 | 18 | 103 |
848 | MODULATORY | 1 | 18 | 35 |
849 | OPERATIONAL | 5 | 18 | 146 |
850 | OPPOSITE | 1 | 18 | 72 |
851 | PROCESSES | 2 | 18 | 100 |
852 | RECURRENT | 11 | 18 | 199 |
853 | REPERTOIRE | 1 | 18 | 33 |
854 | RESULT | 2 | 18 | 99 |
855 | SMALL-BOWEL | 11 | 18 | 92 |
856 | STRUCTURAL | 4 | 18 | 132 |
857 | SYSTEM | 13 | 18 | 228 |
858 | TRANSCRIPTIONAL | 4 | 18 | 238 |
859 | ADVERSE | 5 | 17 | 132 |
860 | ANTIINFLAMMATORY | 3 | 17 | 152 |
# | Word | Recs | TLCS | TGCS |
861 | EXTENDED | 1 | 17 | 119 |
862 | FK506-INDUCED | 5 | 17 | 180 |
863 | FLUORESCENCE | 6 | 17 | 169 |
864 | GRAFT-VS-HOST | 7 | 17 | 90 |
865 | HISTORY | 18 | 17 | 339 |
866 | INFUSED | 2 | 17 | 40 |
867 | KIDNEY-TRANSPLANTS | 7 | 17 | 160 |
868 | LIGHT | 2 | 17 | 116 |
869 | LIVER-GRAFT | 1 | 17 | 60 |
870 | MACROCHIMERISM | 3 | 17 | 57 |
871 | MAST-CELLS | 2 | 17 | 146 |
872 | MEDIATED | 6 | 17 | 137 |
873 | MICROVASCULARIZED | 1 | 17 | 29 |
874 | MODE | 6 | 17 | 75 |
875 | NONIRRADIATED | 1 | 17 | 29 |
876 | NONMYELOABLATED | 1 | 17 | 22 |
877 | PARADIGM | 8 | 17 | 83 |
878 | PATHWAY | 7 | 17 | 267 |
879 | PREVALENCE | 4 | 17 | 190 |
880 | PRIMATE | 7 | 17 | 129 |
881 | RECURRENCE | 4 | 17 | 73 |
882 | REGION | 3 | 17 | 59 |
883 | SENSITIVE | 3 | 17 | 67 |
884 | STATES | 3 | 17 | 150 |
885 | SURVIVING | 5 | 17 | 42 |
886 | TOLERIZATION | 2 | 17 | 47 |
887 | UVEITIS | 5 | 17 | 216 |
888 | VENOUS | 11 | 17 | 155 |
889 | WELL-FUNCTIONING | 1 | 17 | 162 |
890 | ANTI-CD40L | 1 | 16 | 47 |
# | Word | Recs | TLCS | TGCS |
891 | BENEFITS | 7 | 16 | 120 |
892 | COLUMN | 3 | 16 | 230 |
893 | CONSENSUS | 3 | 16 | 198 |
894 | CROSSMATCH-POSITIVE | 1 | 16 | 91 |
895 | CTLA4-IG | 1 | 16 | 281 |
896 | DECEASED-DONOR | 1 | 16 | 58 |
897 | DETECT | 5 | 16 | 114 |
898 | DRUG-MONITORING | 3 | 16 | 113 |
899 | ENHANCE | 3 | 16 | 45 |
900 | EXOGENOUS | 2 | 16 | 314 |
901 | FAVOURABLY | 1 | 16 | 59 |
902 | FK-506-TREATED | 4 | 16 | 97 |
903 | FK506-BASED | 1 | 16 | 103 |
904 | FREQUENCY | 7 | 16 | 228 |
905 | FUNTION | 1 | 16 | 104 |
906 | GLUCOSE | 4 | 16 | 153 |
907 | HCV | 2 | 16 | 61 |
908 | IMMUNOCOMPROMISED | 1 | 16 | 63 |
909 | IMMUNOREACTIVE | 1 | 16 | 47 |
910 | IMPACTS | 1 | 16 | 59 |
911 | IN-VIVO | 10 | 16 | 364 |
912 | LYMPHOKINE-ACTIVATED | 2 | 16 | 106 |
913 | LYMPHOPROLIFERATIVE | 11 | 16 | 261 |
914 | META-ANALYSIS | 4 | 16 | 207 |
915 | ORGAN-INDUCED | 1 | 16 | 29 |
916 | PATTERN | 4 | 16 | 109 |
917 | PILOT | 2 | 16 | 132 |
918 | POPULATION | 7 | 16 | 117 |
919 | PRECONDITIONED | 1 | 16 | 47 |
920 | PREDICT | 2 | 16 | 35 |
# | Word | Recs | TLCS | TGCS |
921 | PROBLEMS | 10 | 16 | 179 |
922 | PROGRESSION | 4 | 16 | 71 |
923 | ROTAMASE | 3 | 16 | 375 |
924 | SEQUENCE-SPECIFIC | 3 | 16 | 69 |
925 | SYNERGISTIC | 8 | 16 | 231 |
926 | THYMIC | 5 | 16 | 62 |
927 | TUBULAR | 5 | 16 | 149 |
928 | 1ST | 3 | 15 | 152 |
929 | 25-YEAR | 2 | 15 | 64 |
930 | ACTIVITIES | 5 | 15 | 116 |
931 | APOPTOTIC | 5 | 15 | 107 |
932 | ATGAM | 2 | 15 | 134 |
933 | AUTOLOGOUS | 5 | 15 | 102 |
934 | BIOASSAY | 1 | 15 | 27 |
935 | BLOCKADE | 6 | 15 | 218 |
936 | CAPACITY | 3 | 15 | 192 |
937 | CD40-CD40 | 1 | 15 | 151 |
938 | COMMON | 3 | 15 | 172 |
939 | DNA | 15 | 15 | 203 |
940 | ESTIMATING | 1 | 15 | 23 |
941 | EVENT | 3 | 15 | 85 |
942 | FAILS | 1 | 15 | 32 |
943 | GASTROINTESTINAL | 7 | 15 | 170 |
944 | HEPATOTROPHIC | 2 | 15 | 70 |
945 | III | 3 | 15 | 179 |
946 | IMMUNOFERRITIN | 1 | 15 | 138 |
947 | IMMUNOGENICITY | 4 | 15 | 69 |
948 | IMMUNOREGULATORY | 3 | 15 | 36 |
949 | IN-SITU | 2 | 15 | 37 |
950 | INHIBITOR | 6 | 15 | 255 |
# | Word | Recs | TLCS | TGCS |
951 | INTERACTION | 8 | 15 | 328 |
952 | NEONATALLY | 1 | 15 | 32 |
953 | OVERGROWTH | 14 | 15 | 201 |
954 | PRECONDITIONING | 3 | 15 | 56 |
955 | PRELIMINARY-STUDY | 2 | 15 | 52 |
956 | PROTOCOL | 5 | 15 | 79 |
957 | RETRANSPLANTATION | 5 | 15 | 151 |
958 | SENSITIZATION | 3 | 15 | 96 |
959 | SEX-DETERMINING | 1 | 15 | 23 |
960 | SPECIMENS | 2 | 15 | 28 |
961 | TIMING | 5 | 15 | 130 |
962 | TOPICAL | 10 | 15 | 336 |
963 | TRANSCRIPTION | 2 | 15 | 139 |
964 | ALLOREACTIVITY | 4 | 14 | 41 |
965 | APPRAISAL | 1 | 14 | 62 |
966 | ARTERY | 6 | 14 | 229 |
967 | BASED | 4 | 14 | 58 |
968 | BLOOD-GROUPS | 2 | 14 | 162 |
969 | CHEMICAL | 6 | 14 | 134 |
970 | CLINICALLY | 6 | 14 | 220 |
971 | CRITICAL | 5 | 14 | 75 |
972 | DISSOCIATION | 4 | 14 | 123 |
973 | EVANS | 2 | 14 | 177 |
974 | FAILURE | 21 | 14 | 361 |
975 | FRONTIER | 3 | 14 | 125 |
976 | GAMMA | 4 | 14 | 50 |
977 | IMPROVED | 7 | 14 | 182 |
978 | INSIGHTS | 1 | 14 | 91 |
979 | LEGACY | 2 | 14 | 28 |
980 | LIPID-METABOLISM | 2 | 14 | 109 |
# | Word | Recs | TLCS | TGCS |
981 | LUNG-TRANSPLANT | 2 | 14 | 31 |
982 | MECHANISTIC | 1 | 14 | 91 |
983 | METABOLIC | 6 | 14 | 130 |
984 | METHODOLOGICAL | 1 | 14 | 22 |
985 | METHYLPREDNISOLONE | 5 | 14 | 142 |
986 | MINNESOTA | 4 | 14 | 64 |
987 | MODULATION | 5 | 14 | 52 |
988 | PATHOGENESIS | 10 | 14 | 431 |
989 | PERSISTS | 2 | 14 | 196 |
990 | POST-TRANSPLANT | 8 | 14 | 277 |
991 | POSTTRANSPLANTATION | 6 | 14 | 141 |
992 | PREPARATIONS | 7 | 14 | 117 |
993 | PROFILES | 5 | 14 | 96 |
994 | REGIMENS | 11 | 14 | 194 |
995 | RESPONSIVENESS | 1 | 14 | 391 |
996 | SUBLETHAL | 4 | 14 | 429 |
997 | SUBPOPULATIONS | 6 | 14 | 145 |
998 | TWO-WAY | 3 | 14 | 40 |
999 | 3-WEEK | 1 | 13 | 136 |
1000 | AMIDE | 1 | 13 | 167 |